Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Apr 12 | 2022Apple Watch Reportedly Faces Glucose Monitoring Delays; Diabeloop to Adapt AID Software for Insulin Pens; MediciNova to Initiate Ph2 NAFLD TrialPurchase Blast
$599
Posted in: Other Apr 06 | 2022Merck Hosts Investor Event Highlighting CV Portfolio and PipelinePurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Apr 04 | 2022AZ/Ionis Ph2b Data @ ACC 2022; Novartis Restructures Pharma Business; Eversense E3 Launched in the US; Dexcom ONE to Launch in UK; New Sota and Kerendia Subanalyses @ ACC 2022; Fractyl Receives IDE for Second Pivotal TrialPurchase Blast
$599
Posted in: Other Mar 31 | 2022Daprodustat US approval in question after vada CRL; Akebia post-CRL investor call highlightsPurchase Blast
$599
Posted in: Glucagon, Other Mar 30 | 2022Zealand Restructures Business to Focus on R&D and Cuts 90% of US Workforce; Samsung and JDRF T1DM Invest in Jaguar Gene TherapyPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Mar 29 | 2022Lannett Initiates Bs-glargine Pivotal Trial; Tirzepatide Meta-analysis Shows No Increased MACE Risk in T2DM; Provention Bio’s PRV-101 Vaccine Positive Final ResultsPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Mar 25 | 2022Dexcom to Implement 4:1 Stock Split; Libre Reimbursed in Japan for Basal-Only Patients; Ypsomed/CamDiab Ltd Collaboration; Movano Q4 '21 and FY ‘21 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Mar 24 | 2022Supersapiens Energy Band Review Published in Rouleur; Arecor Granted US Patent for Insulin Products; 9am.health and Ascensia CollaborationPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Mar 23 | 2022Abbott Sponsors YouTube Video; Novo-Novartis Generic Victoza Suit Settled; Dario Q4 and FY ’21 Earnings; Signs Two New Employer ContractsPurchase Blast
$599
Posted in: Other Mar 21 | 2022Teplizumab BLA Re-submission Accepted by FDA; March 21-24 CHMP AgendaPurchase Blast
$599
Posted in: Glucagon, Other, SGLT2i Mar 17 | 2022Medtronic Appoints New Diabetes EVP and Operating Unit President; Lexicon Loan Suggests No Priority Review for Sota; Diamyd Opens First EU Clinic for Ph3 DIAGNODE-3 Trial; Xeris Launches Gvoke Kit in US; DiaMedica Q4 and FY ’21 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other, SGLT2i Mar 16 | 2022EMPA-KIDNEY Stopped Early; Bayer Files FIGARO-DKD in EU; Glooko Acquires DIABNEXT; Oramed Completes Ph2 Oral Insulin NASH Enrollment; Better Therapeutics Announces BT-001 Pivotal Trial Data in T2DMPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 14 | 2022Dexcom G7 Receives CE Mark; Integrity Applications Completes Name Change to GlucoTrack, Inc.Purchase Blast
$599
Posted in: Basal Insulin, Other Mar 11 | 2022Lilly Initiates First QW Insulin Ph3 Trial (QWINT-3); New Novartis Ph1b T1DM Immunotherapy (MHS552) TrialPurchase Blast
$599
Posted in: GLP-1RA, Glucagon, Glucose Monitoring, Other Mar 10 | 2022Rockley Photonics and Medtronic Collaboration for Non-invasive Wearables; Gan & Lee Dose First Patient with GZR18 in Ph1 T2DM Study; Xeris Biopharma and Zealand Q4 and FY ‘21 Earnings UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other Mar 09 | 2022Novo Nordisk Expands Research Collaboration for Oral Drug Delivery Technologies; eGenesis and University of Miami Collaboration for Human-Compatible Islet CellsPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Mar 08 | 2022Know Labs Prepares for FDA Pre-submission Meeting; FDA Accepts Inventiva’s IND for Ph2 Combination (lanifibranor+empa) Trial; Dexcom CGMs Integrated With Happy BobPurchase Blast